Table 3 Mean (95% confidence interval (CI)) for treatment effects, estimated by a mixed-model linear repeated measures analysisa
From: A multicenter investigation of reablement in Norway: a clinical controlled trial
Reablement group Mean (95% CI) | n | Control group Mean (95% CI) | n | Treatment effect Mean (95% CI) | p-value | |
|---|---|---|---|---|---|---|
Primary outcomes | ||||||
Activity performance COPMb-P (1–10, 10 is high) | ||||||
Baseline | 3.46 (3.24, 3.68) | 707 | 4.00 (3.61, 4.40) | 120 | 0.01 | |
10 weeks | 3.19 (2.98, 3.40) | 588 | 1.57 (1.12, 2.02) | 107 | 1.61 (1.13, 2.10) | < 0.001 |
6 months | 3.19 (2.91, 3.46) | 546 | 1.77 (1.21, 2.33) | 97 | 1.42 (0.82, 2.02) | < 0.001 |
12 months | 2.76 (2.38, 3.15) | 294 | 1.95 (1.17, 2.74) | 52 | 0.81 (−0.04, 1.66) | 0.06 |
Satisfaction with performance COPMb-S (1–10, 10 is high) | ||||||
Baseline | 3.31 (3.07, 3.54) | 705 | 4.14 (3.71, 4.57) | 120 | < 0.001 | |
10 weeks | 3.43 (3.23, 3.64) | 585 | 1.96 (1.50, 2.42) | 107 | 1.47 (0.98, 1.97) | < 0.001 |
6 months | 3.41 (3.15, 3.67) | 543 | 2.04 (1.48, 2.61) | 95 | 1.37 (0.77, 1.98) | < 0.001 |
12 months | 3.14 (2.74, 3.54) | 294 | 2.51 (1.70, 3.32) | 52 | 0.63 (− 0.26, 1.51) | 0.16 |
Secondary outcomes | ||||||
SPPBc Total score (0–12, 12 is high) | ||||||
Baseline | 4.83 (4.50, 5.15) | 697 | 5.61 (4.99, 6.23) | 121 | 0.02 | |
10 weeks | 1.72 (1.48, 1.96) | 574 | 0.39 (− 0.10, 0.88) | 109 | 1.33 (0.80, 1.86) | < 0.001 |
6 months | 1.65 (1.39, 1.91) | 530 | 0.42 (− 0.13, 0.96) | 96 | 1.23 (0.65, 1.82) | < 0.001 |
12 months | 1.46 (1.08, 1.84) | 278 | 0.42 (− 0.34, 1.17) | 52 | 1.03 (0.19, 1.86) | 0.02 |
SPPB Balance (0–4, 4 is best) | ||||||
Baseline | 2.25 (2.11, 2.38) | 697 | 2.39 (2.11, 2.67) | 121 | 0.34 | |
10 weeks | 0.47 (0.35, 0.59) | 573 | 0.13 (−0.11,0.37) | 109 | 0.34 (0.09, 0.59) | 0.01 |
6 months | 0.42 (0.31, 0.53) | 529 | 0.05 (− 0.18, 0.29) | 96 | 0.36 (0.11, 0.62) | 0.01 |
12 months | 0.27 (0.13, 0.41) | 278 | 0.10 (−0.21, 0.40) | 52 | 0.17 (−0.16, 0.51) | 0.31 |
SPPB Walking (0–4, 4 is best) | ||||||
Baseline | 1.80 (1.67, 1.94) | 697 | 2.12 (1.87, 2.37) | 121 | 0.02 | |
10 weeks | 0.56 (0.45, 0.67) | 570 | 0.19 (−0.02, 0.40) | 109 | 0.37 (0.15, 0.59) | < 0.001 |
6 Months | 0.54 (0.40, 0.67) | 529 | 0.17 (−0.08,0.43) | 96 | 0.36 (0.09, 0.63) | 0.01 |
12 Months | 0.46 (0.32, 0.61) | 278 | 0.31 (0.01, 0.62) | 51 | 0.15 (−0.18, 0.48) | 0.38 |
SPPB Sit-to-stand (0–4, 4 is best) | ||||||
Baseline | 0.79 (0.69, 0.89) | 696 | 1.05 (0.84, 1.27) | 121 | 0.03 | |
10 weeks | 0.72 (0.63, 0.81) | 569 | 0.11 (−0.09, 0.31) | 109 | 0.61 (0.39, 0.83) | < 0.001 |
6 Months | 0.71 (0.61, 0.80) | 528 | 0.25 (0.02, 0.47) | 96 | 0.46 (0.21, 0.70) | < 0.001 |
12 Months | 0.69 (0.53, 0.85) | 278 | 0.20 (−0.15, 0.55) | 51 | 0.49 (0.11, 0.87) | 0.01 |
EQ-5D-5 L Mobility (1–5, 1 is best) | ||||||
Baseline | 2.84 (2.75, 2.94) | 696 | 2.65 (2.45, 2.85) | 121 | 0.08 | |
10 weeks | −0.61 (− 0.68, − 0.54) | 579 | − 0.12 (− 0.29, 0.05) | 103 | −0.49 (− 0.68, − 0.31) | < 0.001 |
6 months | −0.57 (− 0.64, − 0.49) | 542 | −0.20 (− 0.38, − 0.01) | 97 | −0.37 (− 0.57, − 0.17) | < 0.001 |
12 months | −0.48 (− 0.59, − 0.36) | 288 | −0.27 (− 0.54, − 0.01) | 54 | 0.20 (− 0.49, 0.08) | 0.17 |
EQ-5D-5 L Personal care (1–5, 1 is best) | ||||||
Baseline | 2.04 (1.93, 2.15) | 697 | 1.83 (1.62, 2.04) | 121 | 0.07 | |
10 weeks | −0.48 (− 0.54, − 0.42) | 581 | − 0.12 (− 0.26, 0.02) | 103 | −0.36 (−-0.51, − 0.21) | < 0.001 |
6 months | −0.40 (− 0.47, − 0.32) | 543 | −0.14 (− 0.31, 0.03) | 97 | −0.26 (− 0.44, − 0.07) | 0.01 |
12 months | −0.42 (− 0.53, − 0.31) | 289 | −0.18 (− 0.41, 0.05) | 54 | −0.24 (− 0.49, − 0.01) | 0.06 |
EQ-5D-5 L Usual activities (1–5, 1 is best) | ||||||
Baseline | 2.87 (2.76. 2.98) | 696 | 2.74 (2.52, 2.96) | 121 | 0.28 | |
10 weeks | −0.57 (− 0.73, − 0.42) | 576 | −0.26 (− 0.62, 0.09) | 103 | −0.31 (− 0.70, 0.08) | 0.12 |
6 months | − 0.64 (− 0.72, − 0.54) | 540 | −0.34 (− 0.54, − 0.14) | 97 | −0.30 (− 0.52, − 0.08) | 0.01 |
12 months | −0.64 (− 0.77, − 0.52) | 290 | −0.38 (− 0.66, − 0.11) | 54 | −0.26 (− 0.56, 0.04) | 0.09 |
EQ-5D-5 L Pain/discomfort (1–5, 1 is best) | ||||||
Baseline | 2.65 (2.53. 2.76) | 693 | 2.66 (2.44, 2.89) | 121 | 0.87 | |
10 weeks | −0.21 (−0.28, − 0.13) | 577 | − 0.87 (− 0.36, 0.01) | 103 | −0.02 (− 0.21, 0.17) | 0.82 |
6 months | − 0.24 (− 0.33, − 0.15) | 537 | −0.13 (− 0.33. 0.06) | 97 | −0.11 (− 0.32, 0.11) | 0.33 |
12 months | − 0.23 (− 0.35, − 0.12) | 54 | −0.21 (− 0.47, 0.05) | 287 | − 0.03 (− 0.31, 0.26) | 0.85 |
EQ-5D-5 L Anxiety/depression (1–5, 1 is best) | ||||||
Baseline | 1.84 (1.75. 1.93) | 692 | 1.68 (1.49, 1.86) | 121 | 0.11 | |
10 weeks | −0.13 (−0.19, − 0.06) | 573 | −0.24 (− 0.39, − 0.10) | 102 | 0.12 (− 0.03, 0.27) | 0.12 |
6 months | −0.16 (− 0.23, − 0.10) | 528 | −0.10 (− 0.26, 0.05) | 95 | −0.06 (− 0.32, 0.11) | 0.48 |
12 months | − 0.19 (− 0.28, − 0.10) | 282 | −0.20 (− 0.39, 0.00) | 54 | 0.00 (− 0.21, 0.22) | 0.98 |
EQ-5D-5 L Health today (0–100, 100 is high) | ||||||
Baseline | 49.85 (48.02, 51.68) | 687 | 53.06 (49.16, 56.95) | 121 | 0.13 | |
10 weeks | 8.36 (6.89. 9.83) | 575 | 2.28 (−1.07, 5.62) | 103 | 6.08 (2.44, 9.72) | < 0.001 |
6 months | 9.14 (7.03, 11.25) | 528 | 1.52 (−2.86, 5.90) | 97 | 7.62 (2.87, 12.37) | < 0.001 |
12 months | 7.55 (5.33, 9.78) | 282 | 4.79 (−0.301, 9.88) | 54 | 2.76 (−2.80, 8.32) | 0.33 |
SOC-13 Sense of coherence (13–91, 91 is high) | ||||||
Baseline | 68.45 (67.34, 69.56) | 658 | 69.45 (67.13, 71,76) | 118 | 0.44 | |
10 weeks | 0.31 (−0.76, 1.38) | 539 | −1.41 (−3.56, 0.73) | 103 | 1.73 (−0.56, 4.01) | 0.14 |
6 months | 0.29 (−1.07, 1.66) | 496 | −2.62 (−5.29, 0.04) | 94 | 2.92 (0.08, 5.75) | 0.04 |
12 months | 0.71 (−1.04, 2.47) | 256 | 0.02 (−3.38, 3.43) | 51 | 0.69 (−3.02, 4.40) | 0.72 |